Calira is a technology company.
Calira has raised $3.0M across 1 funding round.
Calira has raised $3.0M in total across 1 funding round.
Calira has raised $3.0M in total across 1 funding round.
Calira's investors include Boundary Capital Partners LLP, Mogrify, Sana Capital.
Calira is a London-based technology company providing cloud-based lab management software that optimizes R&D lab operations through equipment booking, asset tracking, maintenance scheduling, and utilization analytics.[1][3] Originally launched as Clustermarket in 2016, it rebranded to Calira in October 2025 to target enterprise pharma and biotech amid rising demand for R&D efficiency tools.[1][3] The platform serves academic institutions, SMBs, and major enterprises like Merck, Moderna, Eli Lilly, Takeda, and Lonza, solving inefficiencies such as booking conflicts, underutilized assets, and poor CapEx decisions in labs facing biopharma layoffs and ROI scrutiny.[1] Growth momentum is accelerating with enterprise adoption, AI-driven scheduling features, and hires like industry veteran Edmund to scale for complex pharma needs.[1]
Calira traces its roots to 2016, when it launched as Clustermarket in London, England, founded by CEO and co-founder Johannes Solzbach and team to address fragmented lab scheduling in research environments.[1][3] The idea emerged from recognizing chronic issues in R&D labs—misused equipment, downtime, and ineffective maintenance—prompting an intuitive software solution for equipment coordination and analytics.[3][6] Early traction built among academic institutions and SMBs, with the platform proving resilient during COVID-19 by rapidly scaling to support 150 extra users for single-occupancy spectrometer rooms.[6] A pivotal 2025 rebrand to Calira, coupled with securing Edmund (an industry veteran in lab ops software), marked its shift toward enterprise life sciences, capitalizing on 63% biopharma layoff increases since 2022 and surging interest from Big Pharma.[1]
Calira rides the LabOps optimization wave in life sciences, where biopharma faces market turmoil—63% layoff spikes since 2022—and heightened R&D ROI demands amid AI integration in drug discovery.[1] Timing aligns with post-pandemic lab digitization and enterprise shifts from academic tools to scalable platforms, as firms like Moderna and Takeda seek visibility into expensive assets during cost pressures.[1] Market forces favoring Calira include IoT growth for asset monitoring and competitors like Opentrons (automation robots) or Renovo (HTM services) lacking its booking-centric, AI-scheduling focus.[3] It influences the ecosystem by enabling efficient R&D foundations, informing investments, and accelerating results for pharma/biotech, positioning it as a key enabler in the $XXB lab management software market.[3]
Calira's enterprise pivot and AI enhancements position it for rapid scaling, with enterprise wins signaling 2026 growth in pharma LabOps amid AI-driven R&D trends.[1] Expect deeper integrations with ELNs like Benchling, expanded IoT for predictive maintenance, and potential acquisitions as biopharma consolidates ops tech.[1][2] Its influence could evolve from niche scheduler to holistic platform, shaping efficient labs as ROI scrutiny intensifies—watch for IPO or strategic funding to fuel global expansion, building on its rebrand momentum.[1] This optimized foundation underscores Calira's role in turning lab chaos into R&D acceleration.[1]
Calira has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in June 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2021 | $3.0M Seed | Boundary Capital Partners LLP, Mogrify, Sana Capital |